Literature DB >> 18760875

Regulation of p53R2 and its role as potential target for cancer therapy.

Xin Wang1, Anna Zhenchuk, Klas G Wiman, Freidoun Albertioni.   

Abstract

p53R2, a recently discovered small subunit of human ribonucleotide reductase, is believed to play essential roles in DNA repair, mtDNA synthesis, and protection against oxidative stress. Because of the positive correlation between the level of this protein and drug sensitivity and tumor invasiveness, it constitutes a potential target for anticancer drugs as well as a diagnostic marker in cancer.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18760875     DOI： 10.1016/j.canlet.2008.07.019

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  24 in total

1.  Optimization and evaluation of electroporation delivery of siRNA in the human leukemic CEM cell line.

Authors:  Anna Fyrberg; Kourosh Lotfi
Journal:  Cytotechnology       Date:  2010-10-19       Impact factor: 2.058

Review 2.  Metabolic genes in cancer: their roles in tumor progression and clinical implications.

Authors:  Eiji Furuta; Hiroshi Okuda; Aya Kobayashi; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2010-02-01

3.  E2F1 regulates p53R2 gene expression in p53-deficient cells.

Authors:  Jun-Juan Qi; Ling Liu; Ji-Xiang Cao; Guo-Shun An; Shu-Yan Li; Gang Li; Hong-Ti Jia; Ju-Hua Ni
Journal:  Mol Cell Biochem       Date:  2014-10-14       Impact factor: 3.396

4.  Structural basis on the dityrosyl-diiron radical cluster and the functional differences of human ribonucleotide reductase small subunits hp53R2 and hRRM2.

Authors:  Bingsen Zhou; Leila Su; Yate-Ching Yuan; Frank Un; Norby Wang; Madhukar Patel; Bixin Xi; Shuya Hu; Yun Yen
Journal:  Mol Cancer Ther       Date:  2010-05-18       Impact factor: 6.261

5.  p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis.

Authors:  Chao Jiang; Rui Xu; Xiao-Xing Li; Yan-Yan Wang; Wen-Qian Liang; Ju-Deng Zeng; Shan-Shan Zhang; Xiao-Yi Xu; Yang Yang; Mei-Yin Zhang; Hui-Yun Wang; X F Steven Zheng
Journal:  Cell Cycle       Date:  2017-08-25       Impact factor: 4.534

6.  Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.

Authors:  Anne M Traynor; James P Thomas; Ramesh K Ramanathan; Tarak D Mody; Dona Alberti; George Wilding; Howard H Bailey
Journal:  Invest New Drugs       Date:  2009-12-09       Impact factor: 3.850

7.  DGCR8/ZFAT-AS1 Promotes CDX2 Transcription in a PRC2 Complex-Dependent Manner to Facilitate the Malignant Biological Behavior of Glioma Cells.

Authors:  Fangfang Zhang; Xuelei Ruan; Jun Ma; Xiaobai Liu; Jian Zheng; Yunhui Liu; Libo Liu; Shuyuan Shen; Lianqi Shao; Di Wang; Chunqing Yang; Heng Cai; Zhen Li; Ziyi Feng; Yixue Xue
Journal:  Mol Ther       Date:  2019-11-20       Impact factor: 11.454

8.  Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis.

Authors:  Don B Gammon; Branawan Gowrishankar; Sophie Duraffour; Graciela Andrei; Chris Upton; David H Evans
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

9.  Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphate.

Authors:  Jun Wang; Gregory J S Lohman; JoAnne Stubbe
Journal:  Biochemistry       Date:  2009-12-15       Impact factor: 3.162

10.  E2F4 and ribonucleotide reductase mediate S-phase arrest in colon cancer cells treated with chlorophyllin.

Authors:  Korakod Chimploy; G Dario Díaz; Qingjie Li; Orianna Carter; Wan-Mohaiza Dashwood; Christopher K Mathews; David E Williams; George S Bailey; Roderick H Dashwood
Journal:  Int J Cancer       Date:  2009-11-01       Impact factor: 7.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.